Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02161458 · ClinicalTrials.gov registry record · Phase 4
Escitalopram Effects on CSF Amyloid Beta
A Phase 4 study of Amyloid Beta-protein, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 98
- Enrollment target
- 2
- Study locations
NCT02161458: Completed Phase 4 study of Amyloid Beta-protein, sponsored by University of Pennsylvania.
NCT02161458 is a Phase 4 study of Amyloid Beta-protein that has completed, run by University of Pennsylvania. The registered enrollment target is 98 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02161458, a Phase 4 study of Amyloid Beta-protein, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 98 participants
- Enrollment target
- 2
- Study locations
Study Summary
Alzheimers disease (AD) is a devastating illness, estimated to affect 5 million patients in the United States alone and projected to increase dramatically over the next decades as the population ages unless preventive measures can be developed. The investigators have preliminary evidence that selective serotonin reuptake inhibitor (SSRI) antidepressants lower the amount of amyloid plaques in the human brain. The interventions now propose to study the effects of an SSRI (escitalopram) on levels of amyloid beta peptide (the major constituent of the plaques) in the cerebrospinal fluid (CSF) of cognitively normal older adults.
Primary Outcome
Change in the level of Amyloid Beta peptides (Amyloid Beta 42 and Amyloid Beta 40) in the CSF between the measurement at baseline and the measurement after exposure with escitalopram.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Escitalopram 20mg for 2 weeks
- DRUG Escitalopram 20mg for 8 weeks
- DRUG Escitalopram 30mg for 8 weeks
Study Locations (2)
Missouri
- Washington University - St Louis
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2014-06 |
| Est. Completion | 2019-01 |
| Phase | Phase 4 |
What the finished NCT02161458 record still lists
NCT02161458 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Amyloid Beta-protein appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02161458 reports a single indexed study location in Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02161458 about?
NCT02161458 is a clinical study titled "Escitalopram Effects on CSF Amyloid Beta". Alzheimers disease (AD) is a devastating illness, estimated to affect 5 million patients in the United States alone and projected to increase dramatically over the next decades as the population ages unless preventive measures can be developed. The investigators have preliminary evidence that select...
What is the current status of trial NCT02161458?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 98 participants. The study started on 2014-06. Estimated completion is 2019-01.
What conditions does trial NCT02161458 study?
This clinical trial studies the following conditions: Amyloid Beta-protein.
What interventions are being tested in trial NCT02161458?
The interventions under investigation include: Placebo (DRUG), Escitalopram 20mg for 2 weeks (DRUG), Escitalopram 20mg for 8 weeks (DRUG), Escitalopram 30mg for 8 weeks (DRUG).
Who is sponsoring clinical trial NCT02161458?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02161458 being conducted?
This trial has 2 study locations across Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloid Beta-protein
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02161458's enrollment target sits among peer trials
98 854th of 2000 higher than 1,140 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia